In addition to serving as a surrogate marker of tumor responsiveness to therapy, HIF-1 has rapidly attracted interest both for its potential role as a therapeutic target and its involvement in fundamental physiological and pathophysiological processes, including angiogenesis, resistance to chemotherapy and radiotherapy, tumor invasiveness and poor prognosis of cancer patients [5], [29], [30]. This evidence concerns the gene HIF1A and cancer.